Search for "combinatorial" in Full Text gives 127 result(s) in Beilstein Journal of Organic Chemistry.
Beilstein J. Org. Chem. 2020, 16, 2831–2853, doi:10.3762/bjoc.16.233
Graphical Abstract
Figure 1: Some selected self-sorting outcomes and their qualitative and quantitative assessment.
Figure 2: Illustration of an integrative vs a non-integrative self-sorting.
Figure 3: The pH-driven four-component 2-fold completive self-sorting based on host–guest chemistry.
Figure 4: (a) The monomers 5 and 6 and their H-bonding array. (b) The hydrogen-bonded octameric and tetrameri...
Figure 5: (a) Two new Zn4L6-type cages. (b) The encapsulation of C70 induced distinct reconstitutions within ...
Figure 6: The formation of octahedral cages (a) [Co6(10')4]12+ and (b) [Co6(11')4]12+. (c) The 2-fold complet...
Figure 7: Exchange of Ag+ for Au+ ions in poly-NHC ligand-based organometallic assemblies.
Figure 8: The reversible interconversion between the three-component rectangle [Cu4(16)2(17)2]4+ and the four...
Figure 9: a) Chemical structure of the monomer 20 with its quadruple hydrogen-bonding array and a metal-affin...
Figure 10: Communication between the nanoswitch 21 and the supramolecular assemblies [Cu4(22)2(24)2]4+ or [Cu6(...
Figure 11: (a) The chemical structures and cartoon representations of the switch 25, the decks 26 and 27, and ...
Figure 12: Double self-sorting leads to a catalytic machinery in SelfSORT-II, in which the 46 kHz-nanorotor ac...
Figure 13: ON/OFF control of a networked catalytic catch–release system.
Figure 14: A multicomponent information system for the reversible reconfiguration of switchable dual catalysis....
Figure 15: a) The chemically fueled cascaded ion translocation, monitored by distinct emission colors. b) Work...
Figure 16: Cyclic metallosupramolecular transformations.
Figure 17: Fully reversible multiple-state rearrangement of metallosupramolecular architectures depending upon...
Figure 18: The selective encapsulation and sequential release of guests in a self-sorted mixture of three tetr...
Figure 19: Two catalytic reactions are alternately controlled by a toggle nanoswitch.
Figure 20: A biped walking along a tetrahedral track and unfolding its catalytic action. Adapted with permissi...
Figure 21: A three state supramolecular AND logic gate.
Figure 22: Four-component nanorotor and its catalytic activity. Adapted with permission from (Biswas, P. K.; S...
Beilstein J. Org. Chem. 2020, 16, 2007–2016, doi:10.3762/bjoc.16.167
Graphical Abstract
Figure 1: Schematic representation of binding models between organic cations (simple ammonium, guanidinium, S...
Figure 2: From Schmuck cations to cell-penetrating dipeptides, with schematic representation of the binding m...
Figure 3: Peptide tweezers and cyclic peptides with Schmuck cations for gene transfection.
Figure 4: Evolution from CPPs to CPDs and COCs.
Figure 5: Structure of a) the trifunctional transporter 23 and c) the HaloTag reporter 26. b) Schematic mecha...
Figure 6: CAPA assay for the complex 25, composed of three transporters 23 bound to one streptavidin 24 (with...
Figure 7: Examples from the automated HC imaging of stable HGM cells with HaloTag–GFP on mitochondria, labele...
Figure 8: Evaluation of the automated HC imaging of stable HGM cells with HaloTag–GFP on mitochondria, labele...
Figure 9: a) Automated HC imaging of the cellular uptake of 25, covering the concentration dependence for the...
Figure 10: Examples of automated HC imaging of transiently transfected HeLa cells with HaloTag–GFP on Golgi, l...
Figure 11: Evaluation of the automated HC imaging of the transiently transfected HeLa cells with HaloTag–GFP o...
Beilstein J. Org. Chem. 2020, 16, 1588–1595, doi:10.3762/bjoc.16.131
Graphical Abstract
Scheme 1: a) Building blocks included in this study. b) Antiparallel and parallel constitutional isomers of t...
Figure 1: HPLC–MS chromatograms of a reference library for all possible tripeptide dimers ([M + H]+ ions).
Figure 2: a) HPLC–MS chromatograms of the dimers (CFC)2 and templates YY and FF. b) Amplification of the peak...
Scheme 2: a) Synthesis of the parallel and antiparallel isomers p(CFC)2 and a(CFC)2. b) Templates FF. YY and ...
Figure 3: ITC of YY (30 mM) to a(CFC)2 (1.5 mM) in phosphate buffer (pH 7.4, 100 mM).
Figure 4: Continuously varied NMR measurements of a) p(CFC)2 to YY b) p(CFC)2 to FF c) a(CFC)2 to YY d) a(CFC)...
Figure 5: Job plots derived from the continuously varied NMR measurements of a) p(CFC)2 to YY b) p(CFC)2 to FF...
Beilstein J. Org. Chem. 2020, 16, 1447–1455, doi:10.3762/bjoc.16.120
Graphical Abstract
Figure 1: Selected examples of triazinethione-containing bioactive compounds.
Scheme 1: Strategies for the synthesis of triazinethiones.
Scheme 2: Aldehyde substrate scope of three-component reaction of aldehydes, thiourea and trimethyl orthoform...
Scheme 3: Orthoformate substrate scope of the three component reaction of benzaldehyde, thiourea, and orthofo...
Scheme 4: Gram-scale synthesis of 6aa.
Figure 2: X-ray structure of 6-(methylthio)-4-phenyl-3,4-dihydro-1,3,5-triazine-2(1H)-thione (6aa) with therm...
Scheme 5: Control experiments for investigation of the mechanism.
Scheme 6: Plausible mechanism.
Beilstein J. Org. Chem. 2020, 16, 451–481, doi:10.3762/bjoc.16.42
Graphical Abstract
Scheme 1: [Cu(I)(dap)2]Cl-catalyzed ATRA reaction under green light irradiation.
Scheme 2: Photocatalytic allylation of α-haloketones.
Scheme 3: [Cu(I)(dap)2]Cl-photocatalyzed chlorosulfonylation and chlorotrifluoromethylation of alkenes.
Scheme 4: Photocatalytic perfluoroalkylchlorination of electron-deficient alkenes using the Sauvage catalyst.
Scheme 5: Photocatalytic synthesis of fluorinated sultones.
Scheme 6: Photocatalyzed haloperfluoroalkylation of alkenes and alkynes.
Scheme 7: Chlorosulfonylation of alkenes catalyzed by [Cu(I)(dap)2]Cl. aNo Na2CO3 was added. b1 equiv of Na2CO...
Scheme 8: Copper-photocatalyzed reductive allylation of diaryliodonium salts.
Scheme 9: Copper-photocatalyzed azidomethoxylation of olefins.
Scheme 10: Benzylic azidation initiated by [Cu(I)(dap)2]Cl.
Scheme 11: Trifluoromethyl methoxylation of styryl derivatives using [Cu(I)(dap)2]PF6. All redox potentials ar...
Scheme 12: Trifluoromethylation of silyl enol ethers.
Scheme 13: Synthesis of annulated heterocycles upon oxidation with the Sauvage catalyst.
Scheme 14: Oxoazidation of styrene derivatives using [Cu(dap)2]Cl as a precatalyst.
Scheme 15: [Cu(I)(dpp)(binc)]PF6-catalyzed ATRA reaction.
Scheme 16: Allylation reaction of α-bromomalonate catalyzed by [Cu(I)(dpp)(binc)]PF6 following an ATRA mechani...
Scheme 17: Bromo/tribromomethylation reaction using [Cu(I)(dmp)(BINAP)]PF6.
Scheme 18: Chlorotrifluoromethylation of alkenes catalyzed by [Cu(I)(N^N)(xantphos)]PF6.
Scheme 19: Chlorosulfonylation of styrene and alkyne derivatives by ATRA reactions.
Scheme 20: Reduction of aryl and alkyl halides with the complex [Cu(I)(bcp)(DPEPhos)]PF6. aIrradiation was car...
Scheme 21: Meerwein arylation of electron-rich aromatic derivatives and 5-exo-trig cyclization catalyzed by th...
Scheme 22: [Cu(I)(bcp)(DPEPhos)]PF6-photocatalyzed synthesis of alkaloids. aYield over two steps (cyclization ...
Scheme 23: Copper-photocatalyzed decarboxylative amination of NHP esters.
Scheme 24: Photocatalytic decarboxylative alkynylation using [Cu(I)(dq)(binap)]BF4.
Scheme 25: Copper-photocatalyzed alkylation of glycine esters.
Scheme 26: Copper-photocatalyzed borylation of organic halides. aUnder continuous flow conditions.
Scheme 27: Copper-photocatalyzed α-functionalization of alcohols with glycine ester derivatives.
Scheme 28: δ-Functionalization of alcohols using [Cu(I)(dmp)(xantphos)]BF4.
Scheme 29: Photocatalytic synthesis of [5]helicene and phenanthrene.
Scheme 30: Oxidative carbazole synthesis using in situ-formed [Cu(I)(dmp)(xantphos)]BF4.
Scheme 31: Copper-photocatalyzed functionalization of N-aryl tetrahydroisoquinolines.
Scheme 32: Bicyclic lactone synthesis using a copper-photocatalyzed PCET reaction.
Scheme 33: Photocatalytic Pinacol coupling reaction catalyzed by [Cu(I)(pypzs)(BINAP)]BF4. The ligands of the ...
Scheme 34: Azide photosensitization using a Cu-based photocatalyst.
Beilstein J. Org. Chem. 2019, 15, 2889–2906, doi:10.3762/bjoc.15.283
Graphical Abstract
Figure 1: Examples of bioactive terpenoids.
Figure 2: Repetitive electrophilic and nucleophilic functionalities in terpene and type II PKS-derived polyke...
Figure 3: Abundance and distribution of bacterial terpene biosynthetic gene clusters as determined by genome ...
Figure 4: Terpenoid biosynthesis. Terpenoid biosynthesis is divided into two phases, 1) terpene scaffold gene...
Figure 5: Mechanisms for type I, type II, and type II/type I tandem terpene cyclases. a) Tail-to-head class I...
Figure 6: Functional TC characterization. a) Different terpenes were produced when hedycaryol (18) synthase a...
Figure 7: Selected examples of terpene modification by bacterial CYPs. a) Hydroxylation [89]. b) Carboxylation, h...
Figure 8: Off-target effects observed during heterologous expression of terpenoid BGCs. Unexpected oxidation ...
Figure 9: TC promiscuity and engineering. a) Spata-13,17-diene (39) synthase (SpS) can take C15 and C25 oligo...
Figure 10: Substrate promiscuity and engineering of CYPs. a) Selected examples from using a CYP library to oxi...
Figure 11: Engineering of terpenoid pathways. a) Metabolic network of terpenoid biosynthesis. Toxic intermedia...
Beilstein J. Org. Chem. 2019, 15, 2753–2764, doi:10.3762/bjoc.15.266
Graphical Abstract
Figure 1: a) Tetra ortho-substituted azobenzenes represent a significant advance in terms of Z-isomer stabili...
Figure 2: Minimum-energy geometry calculated for a) the Z-isomer ground state and b) the transition states wi...
Figure 3: Noncovalent index (NCI) surfaces calculated for representative pyrrolidine-based ortho-substituted ...
Figure 4: Noncovalent index (NCI) surfaces and θ dihedral angles (in red) calculated for the minimum-energy g...
Figure 5: Description of the lowest-lying n–π* excitation for the Z-isomers of halogenated 4pzH-F2 and 4pzH-C...
Figure 6: Description of the lowest-lying n–π* excitation for the E-isomers of halogenated 4pzH-F2 and 4pzH-C...
Figure 7: X-ray structures of 4pzMe-F2 (left), 4pzH-F2 (middle) and 4pzMe-OMe2 (right).
Figure 8: Experimental UV–vis spectra of 4pzMe-F2, 4pzMe-Cl2, 4pzMe-OMe2 and 4pzH-F2 in MeCN at 25 µM.
Beilstein J. Org. Chem. 2019, 15, 2113–2132, doi:10.3762/bjoc.15.209
Graphical Abstract
Figure 1: General structure of fulvenes, named according to the number of carbon atoms in their ring. Whilst ...
Figure 2: Generic structures of commonly referenced heteropentafulvenes, named according to the heteroatom su...
Scheme 1: Resonance structures of (a) pentafulvene and (b) heptafulvene showing neutral (1 and 2), dipolar (1a...
Scheme 2: Resonance structures of (a) pentafulvenes and (b) heptafulvenes showing the influence of EDG and EW...
Scheme 3: Reaction of 6,6-dimethylpentafulvene with singlet state oxygen to form an enol lactone via the mult...
Scheme 4: Photosensitized oxygenation of 8-cyanoheptafulvene with singlet state oxygen to afford 1,4-epidioxi...
Figure 3: A representation of HOMO–LUMO orbitals of pentafulvene and the influence of EWG and EDG substituent...
Scheme 5: Reactions of (a) 6,6-dimethylpentafulvene participating as 2π and 4π components in cycloadditions w...
Scheme 6: Proposed mechanism for the [6 + 4] cycloaddition of tropone with dimethylfulvene via an ambimodal [...
Scheme 7: Triafulvene dimerization through the proposed 'head-to-tail' mechanism. The dipolar transition stat...
Scheme 8: Dimerization of pentafulvenes via a Diels–Alder cycloaddition pathway whereby one fulvene acts as a...
Scheme 9: Dimerization of pentafulvenes via frustrated Lewis pair chemistry as reported by Mömming et al. [116].
Scheme 10: Simplified reaction scheme for the formation of kempane from an extended-chain pentafulvene [127].
Scheme 11: The enantioselective (>99% ee), asymmetric, catalytic, intramolecular [6 + 2] cycloaddition of fulv...
Scheme 12: Intramolecular [8 + 6] cycloaddition of the heptafulvene-pentafulvene derivative [22,27].
Scheme 13: Reaction scheme for (a) [2 + 2] cycloaddition of 1,2-diphenylmethylenecyclopropene and 1-diethylami...
Scheme 14: Diels–Alder cycloaddition of pentafulvenes derivatives participating as dienes with (i) maleimide d...
Scheme 15: Generic schemes showing pentafulvenes participating as dienophiles in Diels–Alder cycloadditions wi...
Scheme 16: Reaction of 8,8-dicyanoheptafulvene and styrene derivatives to afford [8 + 2] and [4 + 2] cycloaddu...
Scheme 17: Reaction of 6-aminofulvene and maleic anhydride, showing observed [6 + 2] cycloaddition; the [4 + 2...
Scheme 18: Schemes for Diels–Alder cycloadditions in dynamic combinatorial chemistry reported by Boul et al. R...
Scheme 19: Polymerisation and dynamer formation via Diels–Alder cycloaddition between fulvene groups in polyet...
Scheme 20: Preparation of hydrogels via Diels–Alder cycloaddition with fulvene-conjugated dextran and dichloro...
Scheme 21: Ring-opening metathesis polymerisation of norbornene derivatives derived from fulvenes and maleimid...
Beilstein J. Org. Chem. 2019, 15, 2052–2058, doi:10.3762/bjoc.15.202
Graphical Abstract
Figure 1: Schematic diagram of the S. cerevisiae sesquiterpene overproduction platform and the products of Tv...
Figure 2: Phylogenetic analysis of Tvi09626 with other characterised terpene synthases. Six clades are marked...
Figure 3: GC–MS chromatogram of products in vivo (I), in yeast YZL141 (II), in vitro Tvi09626 with FPP (III),...
Figure 4: Characterisation of Tvi09626 products. (A) Mass spectra of compound 1 at tR = 13.46 min with m/z 22...
Figure 5: GC–MS chromatogram for the metal ion dependency assay.
Beilstein J. Org. Chem. 2019, 15, 1612–1704, doi:10.3762/bjoc.15.165
Graphical Abstract
Figure 1: Various drugs having IP nucleus.
Figure 2: Participation percentage of various TMs for the syntheses of IPs.
Scheme 1: CuI–NaHSO4·SiO2-catalyzed synthesis of imidazo[1,2-a]pyridines.
Scheme 2: Experimental examination of reaction conditions.
Scheme 3: One-pot tandem reaction for the synthesis of 2-haloimidazopyridines.
Scheme 4: Mechanistic scheme for the synthesis of 2-haloimidazopyridine.
Scheme 5: Copper-MOF-catalyzed three-component reaction (3-CR) for imidazo[1,2-a]pyridines.
Scheme 6: Mechanism for copper-MOF-driven synthesis.
Scheme 7: Heterogeneous synthesis via titania-supported CuCl2.
Scheme 8: Mechanism involving oxidative C–H functionalization.
Scheme 9: Heterogeneous synthesis of IPs.
Scheme 10: One-pot regiospecific synthesis of imidazo[1,2-a]pyridines.
Scheme 11: Vinyl azide as an unprecedented substrate for imidazo[1,2-a]pyridines.
Scheme 12: Radical pathway.
Scheme 13: Cu(I)-catalyzed transannulation approach for imidazo[1,5-a]pyridines.
Scheme 14: Plausible radical pathway for the synthesis of imidazo[1,5-a]pyridines.
Scheme 15: A solvent-free domino reaction for imidazo[1,2-a]pyridines.
Scheme 16: Cu-NPs-mediated synthesis of imidazo[1,2-a]pyridines.
Scheme 17: CuI-catalyzed synthesis of isoxazolylimidazo[1,2-a]pyridines.
Scheme 18: Functionalization of 4-bromo derivative via Sonogashira coupling reaction.
Scheme 19: A plausible reaction pathway.
Scheme 20: Cu(I)-catalyzed intramolecular oxidative C–H amidation reaction.
Scheme 21: One-pot synthetic reaction for imidazo[1,2-a]pyridine.
Scheme 22: Plausible reaction mechanism.
Scheme 23: Cu(OAc)2-promoted synthesis of imidazo[1,2-a]pyridines.
Scheme 24: Mechanism for aminomethylation/cycloisomerization of propiolates with imines.
Scheme 25: Three-component synthesis of imidazo[1,2-a]pyridines.
Figure 3: Scope of pyridin-2(1H)-ones and acetophenones.
Scheme 26: CuO NPS-promoted A3 coupling reaction.
Scheme 27: Cu(II)-catalyzed C–N bond formation reaction.
Scheme 28: Mechanism involving Chan–Lam/Ullmann coupling.
Scheme 29: Synthesis of formyl-substituted imidazo[1,2-a]pyridines.
Scheme 30: A tandem sp3 C–H amination reaction.
Scheme 31: Probable mechanistic approach.
Scheme 32: Dual catalytic system for imidazo[1,2-a]pyridines.
Scheme 33: Tentative mechanism.
Scheme 34: CuO/CuAl2O4/ᴅ-glucose-promoted 3-CCR.
Scheme 35: A tandem CuOx/OMS-2-based synthetic strategy.
Figure 4: Biomimetic catalytic oxidation in the presence of electron-transfer mediators (ETMs).
Scheme 36: Control experiment.
Scheme 37: Copper-catalyzed C(sp3)–H aminatin reaction.
Scheme 38: Reaction of secondary amines.
Scheme 39: Probable mechanistic pathway.
Scheme 40: Coupling reaction of α-azidoketones.
Scheme 41: Probable pathway.
Scheme 42: Probable mechanism with free energy calculations.
Scheme 43: MCR for cyanated IP synthesis.
Scheme 44: Substrate scope for the reaction.
Scheme 45: Reaction mechanism.
Scheme 46: Probable mechanistic pathway for Cu/ZnAl2O4-catalyzed reaction.
Scheme 47: Copper-catalyzed double oxidative C–H amination reaction.
Scheme 48: Application towards different coupling reactions.
Scheme 49: Reaction mechanism.
Scheme 50: Condensation–cyclization approach for the synthesis of 1,3-diarylated imidazo[1,5-a]pyridines.
Scheme 51: Optimized reaction conditions.
Scheme 52: One-pot 2-CR.
Scheme 53: One-pot 3-CR without the isolation of chalcone.
Scheme 54: Copper–Pybox-catalyzed cyclization reaction.
Scheme 55: Mechanistic pathway catalyzed by Cu–Pybox complex.
Scheme 56: Cu(II)-promoted C(sp3)-H amination reaction.
Scheme 57: Wider substrate applicability for the reaction.
Scheme 58: Plausible reaction mechanism.
Scheme 59: CuI assisted C–N cross-coupling reaction.
Scheme 60: Probable reaction mechanism involving sp3 C–H amination.
Scheme 61: One-pot MCR-catalyzed by CoFe2O4/CNT-Cu.
Scheme 62: Mechanistic pathway.
Scheme 63: Synthetic scheme for 3-nitroimidazo[1,2-a]pyridines.
Scheme 64: Plausible mechanism for CuBr-catalyzed reaction.
Scheme 65: Regioselective synthesis of halo-substituted imidazo[1,2-a]pyridines.
Scheme 66: Synthesis of 2-phenylimidazo[1,2-a]pyridines.
Scheme 67: Synthesis of diarylated compounds.
Scheme 68: CuBr2-mediated one-pot two-component oxidative coupling reaction.
Scheme 69: Decarboxylative cyclization route to synthesize 1,3-diarylimidazo[1,5-a]pyridines.
Scheme 70: Mechanistic pathway.
Scheme 71: C–H functionalization reaction of enamines to produce diversified heterocycles.
Scheme 72: A plausible mechanism.
Scheme 73: CuI-promoted aerobic oxidative cyclization reaction of ketoxime acetates and pyridines.
Scheme 74: CuI-catalyzed pathway for the formation of imidazo[1,2-a]pyridine.
Scheme 75: Mechanistic pathway.
Scheme 76: Mechanistic rationale for the synthesis of products.
Scheme 77: Copper-catalyzed synthesis of vinyloxy-IP.
Scheme 78: Regioselective product formation with propiolates.
Scheme 79: Proposed mechanism for vinyloxy-IP formation.
Scheme 80: Regioselective synthesis of 3-hetero-substituted imidazo[1,2-a]pyridines with different reaction su...
Scheme 81: Mechanistic pathway.
Scheme 82: CuI-mediated synthesis of 3-formylimidazo[1,2-a]pyridines.
Scheme 83: Radical pathway for 3-formylated IP synthesis.
Scheme 84: Pd-catalyzed urea-cyclization reaction for IPs.
Scheme 85: Pd-catalyzed one-pot-tandem amination and intramolecular amidation reaction.
Figure 5: Scope of aniline nucleophiles.
Scheme 86: Pd–Cu-catalyzed Sonogashira coupling reaction.
Scheme 87: One-pot amide coupling reaction for the synthesis of imidazo[4,5-b]pyridines.
Scheme 88: Urea cyclization reaction for the synthesis of two series of pyridines.
Scheme 89: Amidation reaction for the synthesis of imidazo[4,5-b]pyridines.
Figure 6: Amide scope.
Scheme 90: Pd NPs-catalyzed 3-component reaction for the synthesis of 2,3-diarylated IPs.
Scheme 91: Plausible mechanistic pathway for Pd NPs-catalyzed MCR.
Scheme 92: Synthesis of chromenoannulated imidazo[1,2-a]pyridines.
Scheme 93: Mechanism for the synthesis of chromeno-annulated IPs.
Scheme 94: Zinc oxide NRs-catalyzed synthesis of imidazo[1,2-a]azines/diazines.
Scheme 95: Zinc oxide-catalyzed isocyanide based GBB reaction.
Scheme 96: Reaction pathway for ZnO-catalyzed GBB reaction.
Scheme 97: Mechanistic pathway.
Scheme 98: ZnO NRs-catalyzed MCR for the synthesis of imidazo[1,2-a]azines.
Scheme 99: Ugi type GBB three-component reaction.
Scheme 100: Magnetic NPs-catalyzed synthesis of imidazo[1,2-a]pyridines.
Scheme 101: Regioselective synthesis of 2-alkoxyimidazo[1,2-a]pyridines catalyzed by Fe-SBA-15.
Scheme 102: Plausible mechanistic pathway for the synthesis of 2-alkoxyimidazopyridine.
Scheme 103: Iron-catalyzed synthetic approach.
Scheme 104: Iron-catalyzed aminooxygenation reaction.
Scheme 105: Mechanistic pathway.
Scheme 106: Rh(III)-catalyzed double C–H activation of 2-substituted imidazoles and alkynes.
Scheme 107: Plausible reaction mechanism.
Scheme 108: Rh(III)-catalyzed non-aromatic C(sp2)–H bond activation–functionalization for the synthesis of imid...
Scheme 109: Reactivity and selectivity of different substrates.
Scheme 110: Rh-catalyzed direct C–H alkynylation by Li et al.
Scheme 111: Suggested radical mechanism.
Scheme 112: Scandium(III)triflate-catalyzed one-pot reaction and its mechanism for the synthesis of benzimidazo...
Scheme 113: RuCl3-assisted Ugi-type Groebke–Blackburn condensation reaction.
Scheme 114: C-3 aroylation via Ru-catalyzed two-component reaction.
Scheme 115: Regioselective synthetic mechanism.
Scheme 116: La(III)-catalyzed one-pot GBB reaction.
Scheme 117: Mechanistic approach for the synthesis of imidazo[1,2-a]pyridines.
Scheme 118: Synthesis of imidazo[1,2-a]pyridine using LaMnO3 NPs under neat conditions.
Scheme 119: Mechanistic approach.
Scheme 120: One-pot 3-CR for regioselective synthesis of 2-alkoxy-3-arylimidazo[1,2-a]pyridines.
Scheme 121: Formation of two possible products under optimization of the catalysts.
Scheme 122: Mechanistic strategy for NiFe2O4-catalyzed reaction.
Scheme 123: Two-component reaction for synthesizing imidazodipyridiniums.
Scheme 124: Mechanistic scheme for the synthesis of imidazodipyridiniums.
Scheme 125: CuI-catalyzed arylation of imidazo[1,2-a]pyridines.
Scheme 126: Mechanism for arylation reaction.
Scheme 127: Cupric acetate-catalyzed double carbonylation approach.
Scheme 128: Radical mechanism for double carbonylation of IP.
Scheme 129: C–S bond formation reaction catalyzed by cupric acetate.
Scheme 130: Cupric acetate-catalyzed C-3 formylation approach.
Scheme 131: Control experiments for signifying the role of DMSO and oxygen.
Scheme 132: Mechanism pathway.
Scheme 133: Copper bromide-catalyzed CDC reaction.
Scheme 134: Extension of the substrate scope.
Scheme 135: Plausible radical pathway.
Scheme 136: Transannulation reaction for the synthesis of imidazo[1,5-a]pyridines.
Scheme 137: Plausible reaction pathway for denitrogenative transannulation.
Scheme 138: Cupric acetate-catalyzed C-3 carbonylation reaction.
Scheme 139: Plausible mechanism for regioselective C-3 carbonylation.
Scheme 140: Alkynylation reaction at C-2 of 3H-imidazo[4,5-b]pyridines.
Scheme 141: Two-way mechanism for C-2 alkynylation of 3H-imidazo[4,5-b]pyridines.
Scheme 142: Palladium-catalyzed SCCR approach.
Scheme 143: Palladium-catalyzed Suzuki coupling reaction.
Scheme 144: Reaction mechanism.
Scheme 145: A phosphine free palladium-catalyzed synthesis of C-3 arylated imidazopyridines.
Scheme 146: Palladium-mediated Buchwald–Hartwig cross-coupling reaction.
Figure 7: Structure of the ligands optimized.
Scheme 147: Palladium acetate-catalyzed direct arylation of imidazo[1,2-a]pyridines.
Scheme 148: Palladium acetate-catalyzed mechanistic pathway.
Scheme 149: Palladium acetate-catalyzed regioselective arylation reported by Liu and Zhan.
Scheme 150: Mechanism for selective C-3 arylation of IP.
Scheme 151: Pd(II)-catalyzed alkenylation reaction with styrenes.
Scheme 152: Pd(II)-catalyzed alkenylation reaction with acrylates.
Scheme 153: A two way mechanism.
Scheme 154: Double C–H activation reaction catalyzed by Pd(OAc)2.
Scheme 155: Probable mechanism.
Scheme 156: Palladium-catalyzed decarboxylative coupling.
Scheme 157: Mechanistic cycle for decarboxylative arylation reaction.
Scheme 158: Ligand-free approach for arylation of imidazo[1,2-a]pyridine-3-carboxylic acids.
Scheme 159: Mechanism for ligandless arylation reaction.
Scheme 160: NHC-Pd(II) complex assisted arylation reaction.
Scheme 161: C-3 arylation of imidazo[1,2-a]pyridines with aryl bromides catalyzed by Pd(OAc)2.
Scheme 162: Pd(II)-catalyzed C-3 arylations with aryl tosylates and mesylates.
Scheme 163: CDC reaction for the synthesis of imidazo[1,2-a]pyridines.
Scheme 164: Plausible reaction mechanism for Pd(OAc)2-catalyzed synthesis of imidazo[1,2-a]pyridines.
Scheme 165: Pd-catalyzed C–H amination reaction.
Scheme 166: Mechanism for C–H amination reaction.
Scheme 167: One-pot synthesis for 3,6-di- or 2,3,6-tri(hetero)arylimidazo[1,2-a]pyridines.
Scheme 168: C–H/C–H cross-coupling reaction of IPs and azoles catalyzed by Pd(II).
Scheme 169: Mechanistic cycle.
Scheme 170: Rh-catalyzed C–H arylation reaction.
Scheme 171: Mechanistic pathway for C–H arylation of imidazo[1,2-a]pyridine.
Scheme 172: Rh(III)-catalyzed double C–H activation of 2-phenylimidazo[1,2-a]pyridines and alkynes.
Scheme 173: Rh(III)-catalyzed mechanistic pathway.
Scheme 174: Rh(III)-mediated oxidative coupling reaction.
Scheme 175: Reactions showing functionalization of the product obtained by the group of Kotla.
Scheme 176: Mechanism for Rh(III)-catalyzed oxidative coupling reaction.
Scheme 177: Rh(III)-catalyzed C–H activation reaction.
Scheme 178: Mechanistic cycle.
Scheme 179: Annulation reactions of 2-arylimidazo[1,2-a]pyridines and alkynes.
Scheme 180: Two-way reaction mechanism for annulations reaction.
Scheme 181: [RuCl2(p-cymene)]2-catalyzed C–C bond formation reaction.
Scheme 182: Reported reaction mechanism.
Scheme 183: Fe(III) catalyzed C-3 formylation approach.
Scheme 184: SET mechanism-catalyzed by Fe(III).
Scheme 185: Ni(dpp)Cl2-catalyzed KTC coupling.
Scheme 186: Pd-catalyzed SM coupling.
Scheme 187: Vanadium-catalyzed coupling of IP and NMO.
Scheme 188: Mechanistic cycle.
Scheme 189: Selective C3/C5–H bond functionalizations by mono and bimetallic systems.
Scheme 190: rGO-Ni@Pd-catalyzed C–H bond arylation of imidazo[1,2-a]pyridine.
Scheme 191: Mechanistic pathway for heterogeneously catalyzed arylation reaction.
Scheme 192: Zinc triflate-catalyzed coupling reaction of substituted propargyl alcohols.
Beilstein J. Org. Chem. 2019, 15, 1210–1216, doi:10.3762/bjoc.15.118
Graphical Abstract
Scheme 1: Schematic synthesis of polyfurfulyl alcohol (PFA) incorporating a prolyl peptide catalyst. AA: Amin...
Scheme 2: Utilization of the Ugi four-component reaction (Ugi-4CR) for the synthesis of prolyl pseudo-peptide...
Figure 1: Analysis of the continuous-flow catalytic system producing γ-nitroaldehyde 5 with PFA-supported cat...
Beilstein J. Org. Chem. 2019, 15, 1065–1085, doi:10.3762/bjoc.15.104
Graphical Abstract
Figure 1: γ-Lactam-derived structures considered in this review.
Figure 2: Alkaloids containing an isoindolinone moiety.
Figure 3: Alkaloids containing the 2-oxindole ring system.
Figure 4: Drugs and biological active compounds containing an isoindolinone moiety.
Figure 5: Drugs and biologically active compounds bearing a 2-oxindole skeleton.
Scheme 1: Three-component reaction of benzoic acid 1, amides 2 and DMSO (3).
Scheme 2: Copper-catalysed three-component reaction of 2-iodobenzoic acids 10, alkynylcarboxylic acids 11 and...
Scheme 3: Proposed mechanism for the formation of methylene isoindolinones 13.
Scheme 4: Copper-catalysed three-component reaction of 2-iodobenzamide 17, terminal alkyne 18 and pyrrole or ...
Scheme 5: Palladium-catalysed three-component reaction of ethynylbenzamides 21, secondary amines 22 and CO (23...
Scheme 6: Proposed mechanism for the formation of methyleneisoindolinones 24.
Scheme 7: Copper-catalysed three-component reaction of formyl benzoate 29, amines 2 and alkynes 18.
Scheme 8: Copper-catalysed three-component reaction of formylbenzoate 29, amines 2 and ketones 31.
Scheme 9: Non-catalysed (A) and phase-transfer catalysed (B) three-component reactions of formylbenzoic acids ...
Scheme 10: Proposed mechanism for the formation of isoindolinones 36.
Scheme 11: Three-component reaction of formylbenzoic acid 33, amines 2 and fluorinated silyl ethers 39.
Scheme 12: Three-component Ugi reaction of 2-formylbenzoic acid (33), diamines 41 and isocyanides 42.
Scheme 13: Non-catalysed (A, B) and chiral phosphoric acid promoted (C) three-component Ugi reactions of formy...
Scheme 14: Proposed mechanism for the enantioselective formation of isoindolinones 46.
Scheme 15: Three-component reaction of benzoic acids 33 or 54, amines 2 and TMSCN (52).
Scheme 16: Several variations of the three-component reaction of formylbenzoic acids 33, amines 2 and isatoic ...
Scheme 17: Proposed mechanism for the synthesis of isoindoloquinazolinones 57.
Scheme 18: Three-component reaction of isobenzofuranone 61, amines 2 and isatoic anhydrides 56.
Scheme 19: Palladium-catalysed three-component reaction of 2-aminobenzamides 59, 2-bromobenzaldehydes 62 and C...
Scheme 20: Proposed mechanism for the palladium-catalysed synthesis of isoindoloquinazolinones 57.
Scheme 21: Four-component reaction of 2-vinylbenzoic acids 67, aryldioazonium tetrafluoroborates 68, DABCO·(SO2...
Scheme 22: Plausible mechanism for the formation of isoindolinones 71.
Scheme 23: Three-component reaction of trimethylsilylaryltriflates 77, isocyanides 42 and CO2 (78).
Scheme 24: Plausible mechanism for the three-component synthesis of phthalimides 79.
Scheme 25: Copper-catalysed three-component reaction of 2-formylbenzonitriles 85, arenes 86 and diaryliodonium...
Scheme 26: Copper-catalysed three-component reaction of 2-formylbenzonitriles 85, diaryliodonium salts 87 and ...
Scheme 27: Proposed mechanism for the formation of 2,3-diarylisoindolinones 88, 89 and 92.
Scheme 28: Palladium-catalysed three-component reaction of chloroquinolinecarbaldehydes 97 with isocyanides 42...
Scheme 29: Palladium-catalysed three-component reaction of imines 99 with CO (23) and ortho-iodoarylimines 100....
Scheme 30: Palladium-catalysed three-component reaction of amines 2 with CO (23) and aryl iodide 105.
Scheme 31: Three-component reaction of 2-ethynylanilines 109, perfluoroalkyl iodides 110 and carbon monoxide (...
Scheme 32: Ultraviolet-induced three-component reaction of N-(2-iodoaryl)acrylamides 113, DABCO·(SO2)2 (69) an...
Scheme 33: Proposed mechanism for the preparation of oxindoles 115.
Scheme 34: Three-component reaction of acrylamide 113, CO (23) and 1,4-benzodiazepine 121.
Scheme 35: Multicomponent reaction of sulfonylacrylamides 123, aryldiazonium tetrafluoroborates 68 and DABCO·(...
Scheme 36: Proposed mechanism for the preparation of oxindoles 124.
Scheme 37: Three-component reaction of N-arylpropiolamides 128, aryl iodides 129 and boronic acids 130.
Scheme 38: Proposed mechanism for the formation of diarylmethylene- and diarylallylideneoxindoles 131 and 132.
Scheme 39: Three-component reaction of cyclohexa-1,3-dione (136), amines 2 and alkyl acetylenedicarboxylates 1...
Scheme 40: Proposed mechanism for the formation of 2-oxindoles 138.
Beilstein J. Org. Chem. 2019, 15, 1020–1031, doi:10.3762/bjoc.15.100
Graphical Abstract
Figure 1: Graphical summary of chemically contiguous opioid vaccine approach. A) Illustration of chemically c...
Figure 2: The chemically contiguous heroin–fentanyl haptens designed in this study. Grouping was based on the...
Figure 3: Heroin intermediates used to synthesize HF-1 through HF-9.
Scheme 1: General outline of HF-1, HF-2, HF-3, HF-7 synthesis from fentanyl intermediate 5 and heroin interme...
Scheme 2: Synthesis of fentanyl intermediate 5. Reaction conditions: a) phthalic anhydride, AcOH, reflux, 81%...
Scheme 3: General outline of HF-5, HF-8, HF-9 synthesis from fentanyl intermediates 28 and 46, and heroin int...
Scheme 4: Parallel synthesis of fentanyl domains 25 and 34, for HF-4 and HF-6, respectively.
Scheme 5: General strategy and coupling partners for the chemically contiguous series. aGeneral conditions fo...
Figure 4: Vaccination, titer assessment, and bleed schedule.
Figure 5: Summary of behavioral data for most promising chemically contiguous vaccine HF-7, compared to singu...
Figure 6: Summary of behavioral data for phenethyl-linked haptens HF-4 and HF-6. Bars represent mean ± SEM.
Figure 7: Correlation plots of dual hapten vaccines comparing week 5 and 8 ELISA midpoint titers to ED50 valu...
Beilstein J. Org. Chem. 2019, 15, 906–930, doi:10.3762/bjoc.15.88
Graphical Abstract
Scheme 1: Comparison between a normal sequential reaction and an MCR.
Scheme 2: Synthesis of tetrazoles and hydantoinimide derivatives by consecutive Ugi reactions [17].
Scheme 3: Synthesis of tetrazole-ketopiperazines by two consecutive Ugi reactions [19].
Scheme 4: Synthesis of acylhydrazino bis(1,5-disubstituted tetrazoles) through two hydrazine-Ugi-azide reacti...
Scheme 5: Synthesis of substituted α-aminomethyltetrazoles through two consecutive Ugi reactions (U-4CR and U...
Scheme 6: Synthesis of tetrazole peptidomimetics by direct use of amino acids in two consecutive Ugi reaction...
Scheme 7: One-pot 8CR based on 3 sequential IMCRs [25].
Scheme 8: Combination of IMCRs for the synthesis of substituted 2H-imidazolines [25].
Scheme 9: 6CR involving a tandem combination of Groebke–Blackburn–Bienaymé and Ugi reaction for the synthesis...
Scheme 10: 5CR involving a tandem combination of Groebke–Blackburn–Bienaymé and Passerini reaction for the syn...
Scheme 11: Synthesis of tubugis via three consecutive IMCRs [27].
Scheme 12: Synthesis of telaprevir through consecutive IMCRs [28].
Scheme 13: Another synthesis of telaprevir through consecutive IMCRs [29].
Scheme 14: a) Synthetic sequence for accessing diverse macrocycles containing the tetrazole nucleus by the uni...
Scheme 15: a) Synthetic sequence for the tetrazolic macrocyclic depsipeptides using a combination of two IMCRs...
Scheme 16: Synthesis of cyclic pentapeptoids by consecutive Ugi reactions [32].
Scheme 17: Synthesis of a cyclic pentapeptoid by consecutive Ugi reactions [32].
Scheme 18: MW-mediated synthesis of a cyclopeptoid by consecutive Ugi reactions [33].
Scheme 19: Synthesis of six cyclic pentadepsipeptoids via consecutive isocyanide-based IMCRs [34].
Scheme 20: Microwave-mediated synthesis of a cyclic heptapeptoid through four consecutive IMCRs [35].
Scheme 21: Macrocyclization of bifunctional building blocks containing diacid/diisonitrile and diamine/diisoni...
Scheme 22: Synthesis of steroid-biaryl ether hybrid macrocycles by MiBs [38].
Scheme 23: Synthesis of biaryl ether-containing macrocycles by MiBs [39].
Scheme 24: Synthesis of natural product-inspired biaryl ether-cyclopeptoid macrocycles [40].
Scheme 25: Synthesis of cholane-based hybrid macrolactams by MiBs [41].
Scheme 26: Synthesis of macrocyclic oligoimine-based DCL using the Ugi-4CR-based quenching approach [42].
Scheme 27: Dye-modified and photoswitchable macrocycles by MiBs [43].
Scheme 28: Synthesis of nonsymmetric cryptands by two sequential double Ugi-4CR-based macrocyclizations [44].
Scheme 29: Synthesis of steroid–aryl hybrid cages by sequential 2- and 3-fold Ugi-4CR-based macrocyclizations [46]....
Scheme 30: Ugi-MiBs approach towards natural product-like macrocycles [47].
Scheme 31: a) Bidirectional macrocyclization of peptides by double Ugi reaction. b) Ugi-4CR for the generation...
Scheme 32: MiBs based on the Passerini-3CR for the synthesis of macrolactones [49].
Scheme 33: Template-driven approach for the synthesis of macrotricycles 170 [50].
Beilstein J. Org. Chem. 2019, 15, 881–900, doi:10.3762/bjoc.15.86
Graphical Abstract
Figure 1: A generalized overview of coordination-driven self-assembly.
Figure 2: Examples of self-assembly or self-sorting and subsequent substitution.
Figure 3: Synthesis of salen-type ligand followed by metal-complex formation in the same pot [55].
Figure 4: Otera’s solvent-free approach by which the formation of self-assembled supramolecules could be acce...
Figure 5: Synthesis of a Pd-based metalla-supramolecular assembly through mechanochemical activation for C–H-...
Figure 6: a) Schematic representation for the construction of a [2]rotaxane. b) Chiu’s ball-milling approach ...
Figure 7: Mechanochemical synthesis of the smallest [2]rotaxane.
Figure 8: Solvent-free mechanochemical synthesis of pillar[5]arene-containing [2]rotaxanes [61].
Figure 9: Mechanochemical liquid-assisted one-pot two-step synthesis of [2]rotaxanes under high-speed vibrati...
Figure 10: Mechanochemical (ball-milling) synthesis of molecular sphere-like nanostructures [63].
Figure 11: High-speed vibration milling (HSVM) synthesis of boronic ester cages of type 22 [64].
Figure 12: Mechanochemical synthesis of borasiloxane-based macrocycles.
Figure 13: Mechanochemical synthesis of 2-dimensional aromatic polyamides.
Figure 14: Nitschke’s tetrahedral Fe(II) cage 25.
Figure 15: Mechanochemical one-pot synthesis of the 22-component [Fe4(AD2)6]4− 26, 11-component [Fe2(BD2)3]2− ...
Figure 16: a) Subcomponent synthesis of catalyst and reagent and b) followed by multicomponent reaction for sy...
Figure 17: A dynamic combinatorial library (DCL) could be self-sorted to two distinct products.
Figure 18: Mechanochemical synthesis of dynamic covalent systems via thermodynamic control.
Figure 19: Preferential formation of hexamer 33 under mechanochemical shaking via non-covalent interactions of...
Figure 20: Anion templated mechanochemical synthesis of macrocycles cycHC[n] by validating the concept of dyna...
Figure 21: Hydrogen-bond-assisted [2 + 2]-cycloaddition reaction through solid-state grinding. Hydrogen-bond d...
Figure 22: Formation of the cage and encapsulation of [2.2]paracyclophane guest molecule in the cage was done ...
Figure 23: Formation of the 1:1 complex C60–tert-butylcalix[4]azulene through mortar and pestle grinding of th...
Figure 24: Formation of a 2:2 complex between the supramolecular catalyst and the reagent in the transition st...
Figure 25: Halogen-bonded co-crystals via a) I···P, b) I···As, and c) I···Sb bonds [112].
Figure 26: Transformation of contact-explosive primary amines and iodine(III) into a successful chemical react...
Figure 27: Undirected C–H functionalization by using the acidic hydrogen to control basicity of the amines [114]. a...
Beilstein J. Org. Chem. 2019, 15, 633–641, doi:10.3762/bjoc.15.59
Graphical Abstract
Scheme 1: Synthesis of the propargyloxy calixarene Ca.
Scheme 2: Synthesis of polyaminoazides from polyamines.
Scheme 3: Reaction of 1,3-dibromopropane (4) with sodium azide.
Scheme 4: Formation of the 1,3-oxazinan-2-one ring.
Scheme 5: Formation of the product at m/z 382.2765 u.
Scheme 6: Formation of the components of mixture I.
Figure 1: FTIR spectra (liquid) of mixture I (red) and mixture II (blue).
Figure 2: FTIR spectra (nujol) of Ca (red), CaNS-I (blue) and CaNS-II (green).
Figure 3: CP-MAS NMR spectra of CaNSs.
Figure 4: Structures of guests 6–15.
Beilstein J. Org. Chem. 2019, 15, 521–534, doi:10.3762/bjoc.15.46
Graphical Abstract
Scheme 1: Selectivity levels found in multiple multicomponent reactions. I) Innate selectivity; II) sequentia...
Scheme 2: Indiscriminate double Ugi MCR upon pyridine-2,6-dicarboxylic acid.
Scheme 3: Representative examples of MCR-polymer synthesis. A) Biginelli HTS of polymers; B) Passerini;- C) U...
Scheme 4: Concept of multicomponent macrocyclization.
Scheme 5: Supramolecular structures out of MMCR macrocyclizations.
Scheme 6: Macrocyclization by MMCRs. A) Staudinger MCR; B) boronic-imine MCR.
Scheme 7: Selective Sequential MMCRs. A and B) MCRs involving terephthalaldehyde; C) Multiple GBB processes w...
Scheme 8: Biased substrates for selective MMCRs.
Scheme 9: The Union concept. A) Asinger–Ugi combination; B) Passerini–Ugi/azide from anthranilic acid; C) Pas...
Scheme 10: Relevant examples of consecutive MCRs exploiting the Union Concept. A) Petasis-Ugi combination; B) ...
Scheme 11: Selective MMCRs featuring FGs with distinct reactivity along the sequence. A) Synthesis of aminomet...
Scheme 12: High order MMCRs. A) Ugi/Ugi–Smiles 7C combination; B) imidazoline-N-cyanomethylamide-Ugi union lea...
Scheme 13: Consecutive Ugi 4CR-deprotection–Ugi 4CR strategy towards A) PNA oligomers and B) peptidic tetrazol...
Scheme 14: Sequential Ugi 4CR-deprotection access to cyclopeptoids.
Scheme 15: Stepwise access to 6-aminopenicillanic acid derivative through an Asinger, deprotection, Joullié ap...
Scheme 16: A triple MCR-deprotection approach affording anticancer peptidomimetics.
Beilstein J. Org. Chem. 2019, 15, 445–468, doi:10.3762/bjoc.15.39
Graphical Abstract
Scheme 1: Most common metathesis reactions. Ring-opening metathesis polymerization (ROMP), acyclic diene meta...
Scheme 2: Catalytic cycle for metathesis proposed by Chauvin.
Figure 1: Some of the most representative catalysts for aqueous metathesis. a) Well-defined ruthenium catalys...
Scheme 3: First aqueous ROMP reactions catalyzed by ruthenium(III) salts.
Scheme 4: Degradation pathway of first generation Grubbs catalyst (G-I) in methanol.
Scheme 5: Synthesis of Blechert-type catalysts 19 and 20.
Figure 2: Chemical structure and components of amphiphilic molecule PTS and derivatives.
Scheme 6: RCM of selected substrates in the presence of the surfactant PTS. Conditionsa: The reaction was car...
Scheme 7: RCM reactions of substrates 31 and 33 with the encapsulated G-II catalyst.
Scheme 8: Living ROMP of norbornene derivatives 35 and 36 with phosphine-based catalysts bearing quaternary a...
Scheme 9: Synthesis of water-soluble catalysts 3 and 4 bearing quaternary ammonium tags.
Scheme 10: In situ formation of catalyst 5 bearing a quaternary ammonium group.
Scheme 11: Catalyst recycling of an ammonium-bearing catalyst.
Scheme 12: Removal of the water-soluble catalyst 12 through host–guest interaction with silica-gel-supported β...
Scheme 13: Selection of artificial metathases reported by Ward and co-workers (ArM 1 based on biotin–(strept)a...
Figure 3: In vivo metathesis with an artificial metalloenzyme based on the biotin–streptavidin technology.
Scheme 14: Artificial metathase based on covalent anchoring approach. α-Chymotrypsin interacts with catalyst 66...
Scheme 15: Assembling an artificial metathase (ArM 4) based on the small heat shock protein from M. Jannaschii...
Scheme 16: Artificial metathases based on cavity-size engineered β-barrel protein nitrobindin (NB4exp). The HG...
Scheme 17: Artificial metathase based on cutinase (ArM 8) and resulting metathesis activities.
Scheme 18: Site-specific modification of proteins via aqueous cross-metathesis. The protein structure is based...
Scheme 19: a) Allyl homocysteine (Ahc)-modified proteins as CM substrates. b) Incorporation of Ahc in the Fc p...
Scheme 20: On-DNA cross-metathesis reaction of allyl sulfide 99.
Scheme 21: Preparation of BODIPY-containing profluorescent probes 102 and 104.
Scheme 22: Metathesis-based ethylene detection in live cells.
Scheme 23: First example of stapled peptides via olefin metathesis.
Beilstein J. Org. Chem. 2018, 14, 3059–3069, doi:10.3762/bjoc.14.284
Graphical Abstract
Figure 1: Structures and MICs of Pt-based compounds against P. aeruginosa PAO1.
Figure 2: Transcriptomic analysis of control and cisplatin-treated PAO1 cultures. Heatmap comparing the trans...
Figure 3: Function enrichment of differentially expressed genes from the transcriptomic analysis. A dot-lot f...
Figure 4: Cisplatin fast-kill assay against the P. aeruginosa PAO1, ΔrecA mutant and the ΔrecACOM strain. P. ...
Figure 5: Cisplatin treatment represses T3SS associated virulence. (A) Cisplatin treatment downregulated the ...
Figure 6: P. aeruginosa biofilm killing assay by cisplatin, tobramycin and their combinations. P. aeruginosa ...
Figure 7: Cisplatin treatment attenuates P. aeruginosa infections. CFU mL−1 of PAO1 obtained from corneas wit...
Beilstein J. Org. Chem. 2018, 14, 2991–2998, doi:10.3762/bjoc.14.278
Graphical Abstract
Figure 1: Illustration of coumarin taxonomy.
Scheme 1: Synthesis of oxepin-2-one-annellated coumarins 13 by RCM of acrylates 12.
Scheme 2: Attempted synthesis of pyran-2-one-annellated coumarin 15d via isomerization-RCM.
Scheme 3: Synthesis of aza-annellated coumarin 21 and attempted synthesis of indole 22.
Beilstein J. Org. Chem. 2018, 14, 2881–2896, doi:10.3762/bjoc.14.267
Graphical Abstract
Figure 1: Illustration of a PPI modulator (stabilizer or inhibitor) vs a traditional drug target.
Figure 2: Examples of protein–protein interaction modulators in clinical trials or in clinical use.
Figure 3: Small-molecule inhibitors of PPIs in the β-sliding clamp.
Figure 4: Crystal structure of the RU7 (9)-sliding clamp complex (PDB code 3D1G; adapted from Georgescu et al...
Figure 5: Peptidic inhibitors of PPIs in the sliding clamp.
Figure 6: SSB protein–protein interaction inhibitors identified by HTS.
Figure 7: SSB protein–protein interaction inhibitors identified by FBDD.
Figure 8: Examples of molecules that disrupt the ZipA/FtsZ interaction.
Figure 9: Inhibitors of the NusB/NusE interaction.
Beilstein J. Org. Chem. 2018, 14, 484–498, doi:10.3762/bjoc.14.34
Graphical Abstract
Figure 1: a) Ribbon and b) surface depictions of the cholera toxin: A11 domain in light blue; A12 domain in d...
Figure 2: a) Structure of the cholera toxin showing the location of its carbohydrate binding sites and the st...
Figure 3: Bernardi and co-workers’ designed oligosaccharide mimetics of GM1.
Figure 4: Structure of monomeric ligands. X = amino acid residues, aminoalkyl, 1,2,3 triazoles; n = 1, 2; R =...
Figure 5: Bivalent inhibitor designed and synthesised by Pickens et al.
Figure 6: Bivalent inhibitor designed and synthesized by Arosio et al.
Figure 7: Bivalent inhibitors designed and synthesised by Leaver and Liu.
Figure 8: Bivalent and tetravalent inhibitor designed and synthesised by Pieters, and Bernardi et al.
Figure 9: Cyclic inhibitors synthesised by Kumar et al. for CT.
Figure 10: The star-shaped inhibitors reported by Fan, Hol and co-workers.
Figure 11: Differently sized cyclic decavalent peptide core designed by Zhang et al.
Figure 12: Calix[5]arene core-based pentavalent inhibitor designed by Garcia-Hartjes et al.
Figure 13: Corannulene core-based pentavalent inhibitor designed by Mattarella et al.
Figure 14: Pentavalent inhibitor designed by Pieters and co-workers.
Figure 15: Neoglycoprotein inhibitor based on a non-binding mutant of CTB.
Figure 16: Octavalent inhibitor designed by Pieters, Bernardi and co-workers.
Figure 17: Hetero-bifunctional inhibitor designed by Bundle and co-workers.
Figure 18: Glycopolymers with exchangeable sugar ligands and variable length linkers.
Beilstein J. Org. Chem. 2018, 14, 25–53, doi:10.3762/bjoc.14.3
Graphical Abstract
Figure 1: (A) Gram-negative bacterial membrane with LPS as major component of the outer membrane; (B) structu...
Figure 2: Structures of representative TLR4 ligands: TLR4 agonists (E. coli lipid A, N. meningitidis lipid A ...
Figure 3: (A) Co-crystal structure of the homodimeric E. coli Ra-LPS·hMD-2∙TLR4 complex (PDB code: 3FXI); (B)...
Figure 4: Co-crystal structures of (A) hybrid TLR4·hMD-2 with the bound antagonist eritoran (PDB: 2Z65, TLR4 ...
Scheme 1: Synthesis of E. coli and S. typhimurium lipid A and analogues with shorter acyl chains.
Scheme 2: Synthesis of N. meningitidis Kdo-lipid A.
Scheme 3: Synthesis of fluorescently labeled E. coli lipid A.
Scheme 4: Synthesis of H. pylori lipid A and Kdo-lipid A.
Scheme 5: Synthesis of tetraacylated lipid A corresponding to P. gingivalis LPS.
Scheme 6: Synthesis of pentaacylated P. gingivalis lipid A.
Scheme 7: Synthesis of monophosphoryl lipid A (MPLA) and analogues.
Scheme 8: Synthesis of tetraacylated Rhizobium lipid A containing aminogluconate moiety.
Scheme 9: Synthesis of pentaacylated Rhizobium lipid A and its analogue containing ether chain.
Scheme 10: Synthesis of pentaacylated Rhizobium lipid A containing 27-hydroxyoctacosanoate lipid chain.
Scheme 11: Synthesis of zwitterionic 1,1′-glycosyl phosphodiester: a partial structure of GalN-modified Franci...
Scheme 12: Synthesis of a binary 1,1′-glycosyl phosphodiester: a partial structure of β-L-Ara4N-modified Burkh...
Scheme 13: Synthesis of Burkholderia lipid A containing binary glycosyl phosphodiester linked β-L-Ara4N.
Beilstein J. Org. Chem. 2017, 13, 1486–1497, doi:10.3762/bjoc.13.147
Graphical Abstract
Figure 1: Network motifs. (a) Examples of network motifs composed from different feedback loops. Each design ...
Figure 2: Belousov–Zhabotinsky (BZ) reaction. (a) Classical example of pattern formation in the BZ reaction w...
Figure 3: Examples of synthetic dissipative systems. (a) Feedback cycle of a bilayer network composed of the ...
Figure 4: Design principles applied in synthetic biology. (a) Network topology, mechanism, and the clockwise-...
Figure 5: A retrosynthetic design strategy to implement an oscillating enzymatic reaction network [94]. (a) Schem...
Figure 6: Functions obtained by linking multiple network modules in microfluidic flow reactors (depicted as C...
Figure 7: Influence of molecular structure on the properties of CRNs. (a) Molecular “Swiss army knives” showi...
Figure 8: Network motifs as building blocks for the step-wise build-up of complexity. Chemical reaction netwo...
Beilstein J. Org. Chem. 2017, 13, 1288–1302, doi:10.3762/bjoc.13.125
Graphical Abstract
Figure 1: Hypothesized evolution of ‘life’ and ‘intelligence’.
Figure 2: Structure of maitotoxin, one of the most complex natural products ever tackled by total synthesis. ...
Figure 3: Hypothesis-driven closed-loop learning rationale for Adam and Eve. Hypothesis-driven experimentatio...
Figure 4: Traditional backpropagation neural network machine learning algorithm.
Figure 5: Comparison of architectures of shallow (non-deep) and deep neural networks. Adapted with permission...
Figure 6: Tray of Josiah Wedgwood’s jasper trials from 1773 (copyright Wedgwood Museum; all rights reserved)....
Figure 7: A high-throughput-materials synthesis and characterization facility RAMP, (Rapid Automated Material...
Figure 8: An interactive procedure to design and 3D print bespoke reaction ware to optimization yield and pur...
Figure 9: (Top) Photograph of a small-molecule synthesizer comprised of three modules for deprotection, coupl...
Figure 10: An example of a composition-based descriptor vector that could be used to model or evolve materials...
Figure 11: Example of a simple elitism (copy unchanged), crossover, and point mutation operations acting on th...
Figure 12: A simple example of a two-dimensional fitness functions. The lines represent different evolutionary...
Figure 13: Robotic synthesis and testing of populations of pathogen-resistant polymers evolved by a combinatio...
Figure 14: Net deliverable energy as a function of porous material void fraction at 77 K cycling between 100 a...